Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:28 18/06/2025 BST			5-day change	1st Jan Change
27.20 ^EUR	+0.17%		-1.98%	+40.86%

06-17	Bayer Files for FDA Approval of Gadoquatrane	DJ
06-17	Bayer Seeks US FDA Nod for MRI Contrast Agent Gadoquatrane	MT

BAYER AG : UBS remains Neutral

Published on 15/05/2024 at 08:15, updated on 15/05/2024 at 09:01

In his latest research note, analyst Jo Walton confirms his recommendation. The broker UBS is keeping its Neutral rating. The target price is still set at EUR 32.

Latest news about Bayer AG

Bayer Files for FDA Approval of Gadoquatrane	06-17	DJ
Bayer Seeks US FDA Nod for MRI Contrast Agent Gadoquatrane	06-17	MT
Bayer Files For Approval Of Gadoquatrane In The U.S	06-17	RE
Bayer Files For Approval Of Gadoquatrane In U.S.	06-17	RE
DAX Opens Slightly Higher as China and US Ease Export Restrictions	06-12	RE
HSBC Upgrades Bayer to Buy, Boosts PT	06-11	MT
Bayer at annual high after two buy recommendations	06-11	DP
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies	06-11	CI
Bayer strong in pre-market trading after two buy recommendations	06-11	DP
Bayer extends partnership with Broad Institute	06-11	CF
Frankfurt stock market opening: Dax stable after three weaker days	06-11	DP
BAYER : Potatoes may become a precious commodity	06-10
European shares inch up as Lagarde's remarks offset ECB rate cut	06-05	RE
German Stocks Close Higher as ECB Cuts Rates Again	06-05	MT
Bayer Aktiengesellschaft Presents at 2025 dbAccess Global Consumer Conference, Jun-05-2025 08:30 AM	06-05
Bayer, close to the final round(up)?	06-05
Bayer: promising results in diabetic kidney disease	06-05	CF
Goldman Sachs Upgrades Bayer to Buy, Raises PT	06-05	MT
Bayer: shares rise, on Goldman Sachs' upgrade	06-05	CF
Bayer's Trial Shows Improved Kidney Outcomes With Finerenone-Empagliflozin Combo	06-05	MT
Simultaneous Treatment Start With Finerenone And SGLT-2-Inhibitor Demonstrated Positive Data	06-05	RE
European Midday Briefing : Stocks Higher Ahead of Expected Rate Cut	06-05	DJ
Bayer almost back to its high for the year after Goldman's buy recommendation	06-05	DP
Goldman raises Bayer to 'Buy' - target high at 33 euros	06-05	DP
BAYER AG : Goldman Sachs raises its recommendation to Buy	06-05	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

18/06/2025 - J.P. Morgan European Healthcare Forum

More about the company